Sensitization of mesothelioma cells to platinum-based chemotherapy by GSTπ knockdown

Biochemical and Biophysical Research Communications

Volumn 447, Issue 1, 2014, Pages 77-82

  Chen, Jianli ^a,b   Solomides, Charalambos ^c   Simpkins, Henry ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cisplatin; Glutathione S Transferase ; Mesothelioma

Indexed keywords

ACETYLCYSTEINE; ACTIVATING TRANSCRIPTION FACTOR 2; CISPLATIN; GLUTATHIONE TRANSFERASE P1; MITOGEN ACTIVATED PROTEIN KINASE P38; OXALIPLATIN; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA;

ARTICLE; CANCER CHEMOTHERAPY; CELL GROWTH ASSAY; CHEMOSENSITIZATION; DNA ADDUCT; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GENE SILENCING; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELLS AND CELL LINES;

CISPLATIN; GLUTATHIONE S TRANSFERASE Π; MESOTHELIOMA;

ACETYLCYSTEINE; ACTIVATING TRANSCRIPTION FACTOR 2; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MESOTHELIOMA; ORGANOPLATINUM COMPOUNDS; REACTIVE OXYGEN SPECIES;

EID: 84899476643     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.03.100     Document Type: Article

References (47)

1. B.W. Robinson, and R.A. Lake Advances in malignant mesothelioma N. Engl. J. Med. 353 2005 1591 1603
2. J.P. van Meerbeeck, A. Scherpereel, and V.F. Surmont et al. Malignant pleural mesothelioma: the standard of care and challenges for future management Crit. Rev. Oncol. Hematol. 78 2011 92 111
3. A. Peto, C. Decarli, and F. La Vecchia et al. The European mesothelioma epidemic Br. J. Cancer 79 1999 666 672
4. R.A. Stahel, and W. Weder Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach? Curr. Opin. Oncol. 21 2009 124 130
5. Y. Aelony Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage J. Clin. Oncol. 24 2006 4667 4668
6. D.A. Fennel, J.P. Steele, and J. Shamash et al. Efficacy and safety of first-or second-line irinotecan, cisplatin, and mitomycin in mesothelioma Cancer 109 2007 93 99
7. R. Maruyama, F. Shoji, and T. Okamoto et al. Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma Jpn. J. Clin. Oncol. 35 2005 433 438
8. H.L. Kindler Systemic treatments for mesothelioma: standard and novel Curr. Treat. Options Oncol. 9 2008 171 179
9. A. Xanthopoulos, T.T. Bauer, and T.G. Blum et al. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study J. Occup. Med. Toxicol. 3 2008 1 7
10. J.A. Green, L.J. Robertson, and A.H. Clark Glutathione-S-transferase expression in benign and malignant ovarian tumors Br. J. Cancer 88 1993 235 239
11. X. Cheng, J. Kigawa, and Y. Minagawa et al. Glutathione-S-transferase π expression and glutathione concentration in ovarian carcinoma before and after chemotherapy Cancer 79 1997 521 527
12. P. Surowiak, V. Materna, and I. Kaplenko et al. Augmented expression of metallothionein and glutathione-S-transferese π as unfavorable prognostic factors in cisplatin-treated ovarian cancer patients Virchows Arch. 447 2005 626 633
13. A.G.J. van der Zee, B. van Ommen, and C. Meijer et al. Glutathione-S-transferase activity and isoenzyme composition in benign ovarian tumors, untreated malignant ovarian tumors and malignant tumors after platinum/cyclophosphamide chemotherapy Br. J. Cancer 66 1992 930 936
14. S. Ghazal-Aswad, L. Hogarth, and A.G. Hill et al. The relationship between tumor glutathione concentration, glutathione-S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients Br. J. Cancer 74 1996 468 473
15. K. Ikeda, K. Sakai, and R. Yamamoto et al. Multivariate analysis for prognostic significance of histologic subtype. GSTπ, MDR-1 and p53 in stages II-IV ovarian cancer Int. J. Gynecol. Cancer 13 2003 776 784
16. K.J. Cullen, K.A. Newkirk, and L.M. Schumaker et al. Glutathione-S- transferase π amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors Cancer Res. 63 2003 8097 8102
17. T. Okuyama, Y. Maehara, and K. Endo et al. Expression of glutathione-S-transferase pi and sensitivity in human gastric cancer cells to cisplatin Cancer 74 1994 1230 1236
18. Y. Kodera, K.-I. Isobe, and M. Yamauchi et al. Expression of glutathione-S-transferase α and π in gastric cancer: a correlation with cisplatin resistance Cancer Chem. Pharm. 34 1994 203 208
19. F. Bai, Y. Nakanishi, and M. Kawasaki et al. Immunohistochemical expression of glutathione-S-transferase π can predict chemotherapy response in patients with non-small cell lung carcinoma Cancer 78 1996 416 421
20. M. Pasello, F. Michelacci, and I. Scionti et al. Overcoming glutathione-S-transferase pi-related cisplatin resistance in osteosarcoma Cancer Res. 68 2008 6661 6668
21. A. De Luca, F. Pellizzari Tregno, and A. Sau et al. Glutathione S-transferease P1-1 as a target for mesothelioma treatment Cancer Sci. 104 2013 223 230
22. P. Turella, C. Cerella, and G. Filomeni et al. Proapoptotic activity of new glutathione S-transferase inhibitors Cancer Res. 65 2005 3751 3761
23. M. Pasello, F. Michelacci, and I. Scionti et al. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma Cancer Res. 68 2008 6661 6668
24. 3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism Blood 105 2005 1198 1203
25. A.F. Thevenin, C.L. Zony, and B.J. Bahnson et al. GST pi modulates JNK activity through a direct interaction with JNK substrate, ATF2 Protein Sci. 20 2011 834 848
26. H. Parekh, and H. Simpkins Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells Cancer Chem. Pharm. 37 1996 457 462
27. 2-terminal kinase potentiates apoptotic cell death in response to carboplatin in B lymphoma cells Cancer Chem. Pharm. 62 2008 569 576
28. W.H. Habig, M.J. Pabst, and W.B. Jakoby Glutathione-S-transferases. The first enzymatic step in mercapturic acid formation J. Biol. Chem. 249 1974 7130 7139
29. C. Korch, M.A. Spillman, and T.A. Jackson et al. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination Gynecol. Oncol. 127 2012 241 248
30. A.K.S. Camara, M.L. Riess, and L.G. Kevin et al. Hypothermia augments reactive oxygen species in the guinea pig isolated heart Am. J. Physiol. (Heart Circ. Physiol.) 286 2004 H1289 H1299
31. C. Loetchutinat, S. Kothan, and S. Dechsupa et al. Spectrofluorometric determination of intracellular levels of reactive oxygen species in drug-sensitive and drug-resistant cancer cells using the 2′,7′- dichlorofluorescein diacetate assay Radiat. Phys. Chem. 72 2005 323 331
32. D.M. Townsend, and K.D. Tew The role of glutathione-S-transferase in anti-cancer drug resistance Oncogene 22 2003 7369 7375
33. N. Ban, Y. Takahashi, and T. Takayama et al. Transfection of glutathione-S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan and etoposide Cancer Res. 56 1996 3577 3582
34. T. Coelho, D. Adams, and A. Silva et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis N. Engl. J. Med. 369 2013 819 829
35. X. Xu, K. Xie, and X.-Q. Zhang et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug Proc. Natl. Acad. Sci. 110 2013 18638 18643
36. P. Bragado, A. Armesilla, and A. Silva et al. Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation Apoptosis 12 2007 1733 1742
37. R. Eguchi, Y. Fujimori, and H. Takeda et al. Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells J. Cell. Physiol. 226 2011 762 768
38. 3 in the acute promyelocytic leukemia cell line NB4 Ann. Hematol. 85 2006 681 687
39. A.J. Berger, H.M. Kluger, and N. Li et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival Cancer Res. 63 2003 8103 8107
40. S. Knippen, T. Loning, and V. Muller et al. Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas Anticancer Res. 29 2009 183 190
41. D. Duffey, S. Dolgilevich, and S. Razzouk et al. Activating transcription factor-2 (ATF2) in survival mechanisms in head and neck carcinoma cells Head Neck 33 2011 1586 1599
42. A. Bhoumik, V. Ivanov, and Z. Ronai Activating transcription factor 2-derived peptides alter resistance of humor tumor cell lines to ultraviolet irradiation and chemical treatment Clin. Cancer Res. 7 2001 331 342
43. 2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair J. Biol. Chem. 278 2003 20562 20592
44. E. Lau, and Z.A. Ronai ATF2-at the crossroads of nuclear and cytosolic functions J. Cell Sci. 125 2012 1 10
45. A. De Luca, L. Federici, and M. De Canio et al. New insights into the mechanism of JNK1 inhibition by glutathione transferase P1-1 Biochemistry 51 2012 7304 7312
46. E. Raymond, S. Faivre, and S. Chaney et al. Cellular and molecular pharmacology of oxaliplatin Mol. Cancer Ther. 1 2002 227 235
47. J. Yang, J. Parsons, and N.H. Nicolay et al. Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy Oncogene 29 2010 463 468